Trial reportJournal of applied physiology (Bethesda, Md. : 1985)2026
Beneficial vascular effects of oral phosphatidylserine supplementation in type 2 diabetes.
Neil J McMillan, Marc A Augenreich, Francisco I Ramirez-Perez, Gavin Power, Katherine Burr, Olubodun M Lateef, Manikandan Nagarajan, Christopher A Foote, Natnicha Imkaew, Thomas J Jurrissen and 7 more
Abstract readRandomized Controlled Trial
In one paragraphTrial report in Journal of applied physiology (Bethesda, Md. : 1985), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Marc A AugenreichNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0002-0719-8799 Francisco I Ramirez-PerezNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0003-4920-383X Gavin PowerNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.
Katherine BurrNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.
Olubodun M LateefNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0002-4207-3422 Manikandan NagarajanNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0003-2462-2333 Christopher A FooteNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.
Thomas J JurrissenNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.
Yoskaly Lazo-FernandezNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0001-5793-7652 Edgar E Betancourt-CortesNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.
Larissa Ferreira-SantosNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0001-5738-1623 Jesus H Beltran-OrnelasNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.
Camila Manrique-AcevedoNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0001-9341-404X Luis A Martinez-LemusNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0002-6559-5717 Funding
Targeting ADAM17 activity for correction of vascular insulin resistance in type 2 diabetesR01HL151384 · UNIVERSITY OF MISSOURI-COLUMBIA · 2025 to 2025
$682kAmerican Heart Association (AHA) 23PRE1020897American Heart Association (AHA) 24EIA1248820American Heart Association (AHA) 25DIVSUP1463861American Heart Association (AHA) 26PRE1559973HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL151384NHLBI NIH HHS R01 HL151384Sao Paulo Research Foundation 2024/09267-4
6 · The paper itselfAbstract
Endothelial insulin resistance is a characteristic of type 2 diabetes (T2D) that contributes to reduced nitric oxide bioavailability, impaired vasodilation, and arterial stiffening. We recently provided evidence that endothelial insulin resistance in T2D may be attributed to the shedding of insulin receptors by ADAM17. As prior work by others suggested that exogenous phosphatidylserine (PS) can competitively inhibit ADAM17, we hypothesized that oral PS supplementation would improve vascular function in diabetes. First, we corroborated the ability of PS to interact with and inhibit ADAM17 activity using in vitro approaches and experiments in isolated arteries. Next, we tested the vascular effects of PS in diabetic mice (
Indexed as
Diabetes Mellitus, Type 2PhosphatidylserinesADAM17 ProteinAdministration, OralAnimalsDietary SupplementsDouble-Blind MethodEndothelial CellsEndothelium, VascularFemaleHumansInsulinInsulin ResistanceMaleMiceMice, Inbred C57BLADAM17 ProteinADAM17 protein, humanInsulinPhosphatidylserinesdiabetesphosphatidylserinevascular function
Identifiers
PMID42312814
PMCPMC13404116
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390